Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Merck, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: $295.3B

Website: http://www.merck.ph

Clinical Trials

Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001)

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Biological: MK-4166
Biological: Pembrolizumab

First Posted Date: 2014-05-07

Last Posted Date: 2021-01-28

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 116

Registration Number: NCT02132754

Efficacy and Safety of Grazoprevir (MK-5172), Elbasvir (MK-8742), and Sofosbuvir for Chronic Infection With Hepatitis C Virus Genotypes 1 and 3 (MK-5172-074)

Phase 2

Completed

Conditions: Hepatitis C

Interventions: Drug: Grazoprevir/Elbasvir FDC
Drug: Sofosbuvir

First Posted Date: 2014-05-07

Last Posted Date: 2021-02-05

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 143

Registration Number: NCT02133131

Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292)

Phase 3

Completed

Conditions: HIV Infection

Interventions: Drug: Reformulated Raltegravir
Drug: Raltegravir
Drug: TRUVADA™
Drug: Placebo to Reformulated Raltegravir
Drug: Placebo to Raltegravir

First Posted Date: 2014-05-06

Last Posted Date: 2019-01-30

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 802

Registration Number: NCT02131233

A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)

Phase 1

Completed

Conditions: Melanoma
Solid Tumors

Interventions: Biological: Pembrolizumab
Drug: Dabrafenib
Drug: Placebo
Drug: Trametinib

First Posted Date: 2014-05-05

Last Posted Date: 2022-08-01

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 184

Registration Number: NCT02130466

Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)

Phase 2

Terminated

Conditions: HIV Infections

Interventions: Drug: Raltegravir (MK-0518)
Drug: Tenofovir
Drug: Nevirapine
Drug: Emtricitabine
Drug: Lamivudine
Drug: Lopinavir
Drug: Ritonavir
Drug: Atazanavir
Drug: Darunavir

First Posted Date: 2014-04-17

Last Posted Date: 2019-04-08

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 11

Registration Number: NCT02116660

Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Chronic Hepatitis C Participants With Child-Pugh (CP)-B Hepatic Insufficiency (MK-5172-059)

Phase 2

Completed

Conditions: Chronic Hepatitis C

Interventions: Drug: Grazoprevir
Drug: Elbasvir
Drug: MK-5172A

First Posted Date: 2014-04-16

Last Posted Date: 2019-06-26

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 40

Registration Number: NCT02115321

Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014)

Phase 1

Completed

Conditions: Hepatic Impairment
Type 2 Diabetes Mellitus

Interventions: Drug: Ertugliflozin 15 mg

First Posted Date: 2014-04-16

Last Posted Date: 2018-08-20

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 16

Registration Number: NCT02115347

A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020)

Phase 3

Completed

Conditions: Papilloma Viral Infection

Interventions: Biological: V503
Biological: GARDASIL

First Posted Date: 2014-04-15

Last Posted Date: 2018-11-01

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 500

Registration Number: NCT02114385

Locations: 🇧🇪
Sanofi Pasteur MSD Investigational Site 1002, Ghent, Belgium
🇧🇪
Sanofi Pasteur MSD Investigational Site 1003, Leuven, Belgium
🇧🇪
Sanofi Pasteur MSD Investigational Site 1001, Wilrijk, Belgium

and more 4 locations

Study Assessing Single and Multiple Doses of IDX21459 in Healthy and HCV-Infected Subjects

Phase 1

Terminated

Conditions: Chronic Hepatitis C

Interventions: Drug: IDX21459
Drug: Matching Placebo

First Posted Date: 2014-04-14

Last Posted Date: 2016-01-26

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 48

Registration Number: NCT02112942

Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)

Phase 3

Completed

Conditions: Hepatitis C Infection

Interventions: Drug: Grazoprevir + Elbasvir
Drug: Ribavirin

First Posted Date: 2014-04-07

Last Posted Date: 2021-02-05

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 420

Registration Number: NCT02105701

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy